Maan Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Maan Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $1.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Maan Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $1.9M Trade | TransData Nexus

Maan Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $1.9M Total Trade · DGFT Verified

Maan Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $1.9M across 4 products in 3 therapeutic categories. Based on 37 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cefixime ($950.0K), Metoclopramide ($450.0K), Ketoconazole ($300.0K).

Maan Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Maan Pharmaceuticals Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Maan Pharmaceuticals Limited? — Company Overview & Market Position

Maan Pharmaceuticals Limited, established on May 13, 1988, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24231GJ1988PLC010699. It operates as a non-government entity with an authorized capital of ₹7.5 crore and a paid-up capital of ₹7.14 crore.

The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Maan Pharmaceuticals has a significant presence in the Indian pharmaceutical industry and is expanding its footprint in global markets. Its product portfolio includes internationally accepted formulations of Buprenorphine and Naltrexone, available in both branded and generic forms.

As of the latest available data, Maan Pharmaceuticals employs between 51 and 200 individuals. The company's registered office is located at 506 Samedh, Near Associated Petrol Pump, C.G. Road, Ellisbridge, Ahmedabad, Gujarat, 380006, India.

What Does Maan Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cefixime$950.0K

Product Portfolio — Top 4 by Export Value

Maan Pharmaceuticals Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cefixime	Advanced Antibiotics	$950.0K	19	0.5%	13
2	Metoclopramide	Gastrointestinal	$450.0K	9	2.0%	4
3	Ketoconazole	Antifungals	$300.0K	6	0.8%	11
4	Meropenem	Advanced Antibiotics	$150.0K	3	0.1%	8

Maan Pharmaceuticals Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $1.9M. The top category is Advanced Antibiotics (59.5% of portfolio), followed by Gastrointestinal (24.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Maan Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Maan Pharmaceuticals operates state-of-the-art manufacturing facilities in Mehsana and Vapi, Gujarat, India. These facilities are WHO-GMP certified, ensuring adherence to international quality standards. The Mehsana plant specializes in the production of various dosage forms, including tablets, hard and soft gelatin capsules, orally disintegrating films, sachets, syrups, suspensions, creams, ointments, and injections, such as ampoules and vials.

The Vapi facility complements the Mehsana plant, contributing to the company's capacity to meet both domestic and international demand. Maan Pharmaceuticals emphasizes the use of innovative technology in its manufacturing processes, supported by advanced automation systems that monitor critical parameters like air distribution, temperature, humidity, and cleaning processes.

3Key Leadership

Maan Pharmaceuticals Limited is led by a team of experienced directors:

Hemendra Atmaram Patel
Nilesh Narendrakumar Ranka
Anil Hari Bhambhani
Vishnu Motibhai Desai
Lalbhai Maljibhai Desai

These directors oversee the strategic direction and operations of the company, ensuring alignment with its mission to provide high-quality pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Maan Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Maan Pharmaceuticals Limited has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are WHO-GMP certified, which is a prerequisite for market access in these regions.

While specific regulatory filings and approvals in these markets are not publicly disclosed, the company's adherence to international quality standards positions it favorably for market entry. The focus on de-addiction treatment formulations, such as Buprenorphine and Naltrexone, aligns with the therapeutic needs in these regions, potentially facilitating partnerships and distribution agreements.

2Emerging Markets

Maan Pharmaceuticals Limited has been actively expanding its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's commitment to addressing unmet medical needs, particularly in de-addiction treatments, resonates with the healthcare challenges in these regions.

The WHO-GMP certification of Maan Pharmaceuticals' manufacturing facilities enhances its credibility and facilitates access to these markets. By offering affordable and high-quality pharmaceutical products, the company aims to improve patient outcomes and establish long-term business relationships in these regions.

Geographic Strategy

Maan Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Maan Pharmaceuticals Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's WHO-GMP certification indicates compliance with international manufacturing standards, which is a critical factor for FDA approval.

To gain FDA approval for its products, Maan Pharmaceuticals would need to submit the necessary applications and undergo inspections as required by the FDA. The company's focus on high-quality de-addiction treatment formulations positions it to meet the stringent requirements of the FDA.

2WHO & EU GMP

Maan Pharmaceuticals Limited's manufacturing facilities are WHO-GMP certified, ensuring adherence to international quality standards. This certification is essential for market access in various countries, including those in the European Union.

While specific EU GMP certification details are not publicly disclosed, the WHO-GMP certification serves as a strong foundation for compliance with EU regulations. The company's commitment to quality and innovation enhances its potential for successful market entry and partnerships within the EU.

Maan Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Maan Pharmaceuticals Limited operates in a competitive landscape, particularly in the de-addiction treatment segment. While specific market share data is not publicly available, the company's focus on Buprenorphine and Naltrexone formulations positions it in direct competition with other pharmaceutical companies offering similar products.

The company's WHO-GMP certified manufacturing facilities and commitment to quality provide a competitive edge in meeting international standards. By addressing unmet medical needs in the de-addiction treatment space, Maan Pharmaceuticals aims to differentiate itself and capture market share in both domestic and international markets.

2Key Differentiators

Maan Pharmaceuticals Limited's key differentiators include its focus on de-addiction treatment formulations, such as Buprenorphine and Naltrexone, and its commitment to innovative technology in manufacturing processes. The company's WHO-GMP certified facilities ensure adherence to international quality standards, enhancing its credibility in global markets.

Additionally, Maan Pharmaceuticals' strategic geographic diversification and emphasis on addressing unmet medical needs in emerging markets position it as a responsive and adaptable player in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Maan Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Maan Pharmaceuticals Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's WHO-GMP certified facilities and adherence to international quality standards underscore its reliability as a supplier.

The company's focus on de-addiction treatment formulations, such as Buprenorphine and Naltrexone, addresses significant unmet medical needs,

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Maan Pharmaceuticals Limited

How many pharmaceutical products does Maan Pharmaceuticals Limited export from India?

Maan Pharmaceuticals Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Cefixime ($950.0K), Metoclopramide ($450.0K), Ketoconazole ($300.0K), Meropenem ($150.0K). Total export value is $1.9M.

What is Maan Pharmaceuticals Limited's total pharmaceutical export value?

Maan Pharmaceuticals Limited's total pharmaceutical export value is $1.9M, based on 37 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Maan Pharmaceuticals Limited cover?

Maan Pharmaceuticals Limited exports across 3 therapeutic categories. The largest are Advanced Antibiotics (59.5%, 2 products), Gastrointestinal (24.3%, 1 products), Antifungals (16.2%, 1 products).

Get Full Maan Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.